Assessing potential impact of 2015 American Thyroid Association guidelines on community standard practice for I-131 treatment of low-risk differentiated thyroid cancer: case study of Jordan

Juweid, Malik E.; Rabadi, Nidal J.; Tülchinsky, Mark; Aloqaily, Mohammed; Arabiat, Majd; Ain, Gassem Abu; Hawari, Hussam Al; Al-Momani, Munther; Mismar, Ayman; Abulaban, Amr; Taha, Ibrahim; Alhouri, Abdullah; Zayed, Ayman A.; Albsoul, Nader; Al‐Abbadi, Mousa A.

doi:10.1007/s12020-021-02698-x

Cited by 4 publications

(2 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As a prototype in the field, radioactive iodine-and sodium iodide symporter (NIS)-based theranostics have been used for the treatment of patients with differentiated thyroid cancer (DTC) for more than 40 years, even before coining the term "theranostics". Approximately 600 patients with DTC are treated every year with 131 I in Jordan with subsequent follow-up using diagnostic 131 I whole-body scans [9][10][11] . The largest five public medical centers in Jordan, in addition to some private centers use diagnostic and therapeutic 131 I doses in the assessment and treatment of DTC and hyperthyroidism.…”

Section: Results and Discussion Theranostics Applications In Jordanmentioning

confidence: 99%

Theranostics in the Arab World; Achievements & Challenges

Al‐Ibraheem¹,

Abdlkadir²

2022

JMJ

View full text Add to dashboard Cite

In nuclear medicine, theranostics (combining therapy and diagnostics in one platform) is made possible through the utilization of radiopharmaceuticals for both therapeutic and diagnostic purposes by targeting one specific tumor receptor or certain molecular pathway.To make radiopharmaceuticals biologically relevant compounds, receptor ligands must be labeled with radionuclides. The possible applications are multifold and include: in vivo visualization of tumor biology; diagnosis and tumor staging; therapy planning and treatment of specific tumors.The application of theranostics results in giving the right treatment to the right patient at the right time, which is expected to improve therapeutic efficacy and increase overall compliance to therapy. For example, theranostics can be used to determine the heterogeneity of cancer lesions, which is one of the most difficult aspects of therapeutic success, allow the identification of patients who will benefit from therapy, avoid unnecessary conventional therapies, and implement salvage treatments for those who need them.The use of theranostics has seen unprecedented value for cancer patients in the last decade. Several radiopharmaceuticals are currently in use in clinical practice (e.g., [68Ga/177Lu] DOTATATE), while dozens more are still in the preclinical stages.The goal of this review article is to cover the current and future status of nuclear theranostics, particularly in the Arab world, with a focus on expanding the discipline beyond neuroendocrine tumors, castration-resistant prostate cancers, and differentiated thyroid cancers. Furthermore, representatives from different Arab countries were invited to describe their recent understanding and contributions to drive innovation in this evolving field.

show abstract

Section: Results and Discussion Theranostics Applications In Jordanmentioning

confidence: 99%

Theranostics in the Arab World; Achievements & Challenges

Al‐Ibraheem¹,

Abdlkadir²

2022

JMJ

View full text Add to dashboard Cite

show abstract

“…In general, the prognosis of well-differentiated thyroid cancers is believed to be excellent, particularly for localized DTC and thyroid cancer with regional lymph node metastases [ 8 ]. To our knowledge, there is only limited research work on prognostic factors and outcomes of DTC, specifically for Middle Eastern and Arab populations [ 9 , 10 , 11 , 12 ].…”

Section: Introductionmentioning

confidence: 99%

Long-Term Survival Analysis and Prognostic Factors of Arabic Patients with Differentiated Thyroid Carcinoma: A 20-Year Observational Study at the King Hussein Cancer Center (KHCC) Involving 528 Patients

Al‐Ibraheem

Al-Rasheed

Mashhadani

et al. 2023

Cancers

Self Cite

View full text Add to dashboard Cite

DTC accounts for the majority of endocrine tumors. While the incidence of thyroid cancer has been increasing globally over the past few decades, papillary thyroid carcinoma (PTC) generally shows an excellent prognosis, except in cases with aggressive clinicopathological features. This study aimed to assess the 5- and 10-year overall survival (OS) and progression-free survival (PFS) of 528 Arabic patients diagnosed with primary DTC from 1998 to 2021. Additionally, the study aimed to analyze the impact of various factors on both OS and PFS. An univariable survival analysis was conducted using Kaplan–Meier curves. The 5- and 10-year OS for patients with DTC have exceeded 95%. Additionally, PFS showed very good rates (ranging between 96.5 and 85% at 5 and 10 years, respectively). Age, male gender, risk of recurrence, and distant metastasis were identified as the main negative prognostic factors for both OS and PFS, while RAI treatment was found to be a significant factor in improving OS. Moreover, adherence to the King Hussein Cancer Center’s (KHCC) CPG demonstrated significant improvement in PFS. These findings highlight common prognostic factors and favorable outcomes in Arabic patients with DTC treated at a tertiary cancer center using standard of care approaches.

show abstract

The Prospective Implementation of the 2015 ATA Guidelines and Modified ATA Recurrence Risk Stratification System for Treatment of Differentiated Thyroid Cancer in a Canadian Tertiary Care Referral Setting

Ghaznavi

et al. 2022

Thyroid

View full text Add to dashboard Cite

Assessing potential impact of 2015 American Thyroid Association guidelines on community standard practice for I-131 treatment of low-risk differentiated thyroid cancer: case study of Jordan

Cited by 4 publications

References 32 publications

Theranostics in the Arab World; Achievements & Challenges

Theranostics in the Arab World; Achievements & Challenges

Long-Term Survival Analysis and Prognostic Factors of Arabic Patients with Differentiated Thyroid Carcinoma: A 20-Year Observational Study at the King Hussein Cancer Center (KHCC) Involving 528 Patients

The Prospective Implementation of the 2015 ATA Guidelines and Modified ATA Recurrence Risk Stratification System for Treatment of Differentiated Thyroid Cancer in a Canadian Tertiary Care Referral Setting

Contact Info

Product

Resources

About